Frontiers in Clinical Drug Research - Alzheimer Disorders Volume 5.

Intro -- CONTENTS -- PREFACE -- List of Contributors -- Should Physicians Screen for Dementia in the Primary Care Setting? -- INTRODUCTION -- SECTION 1: SHOULD WE SCREEN FOR DEMENTIA? -- Considerations in Screening for a Disease -- Does Dementia Pass Muster as a Disease Worthy of Screening? -- CRITERION 1: How Prevalent and Costly is Alzheimer's disease? -- CRITERION 2: Are Early Stages of Dementia not Obvious? -- CRITERION 3: Are Screening Tools Cheap and Effective? -- CRITERION 4: Does the Potential Harm from a False Positive or False Negative Test Outweigh the Positive Benefit from Screening? -- Criterion 5: Does Earlier Diagnosis of Dementia or Cognitive Impairment Make a Difference? -- Potential Non-Disease Indirect Benefits of Screening for Dementia -- Potential Benefit of Early Detection #1: Alerting Physician to Potential Medication Compliance Problems -- Potential Benefit of Early Detection #2: Alerting Physicians to the Risk of Post-Operative Delirium -- Potential Benefit of Early Detection #3: Additional Time for Family Planning -- Potential Benefit of Early Detection #4: Assessing Patient's Competence at Work and Managing Finances -- Potential Benefit of Early Detection #5: Identifying Unsafe Drivers Before it is too late -- Potential Benefit #6-Identification of Potentially Reversible Dementias-and Reversing Them -- Potential Benefit #7: Identification of Patients for Research Program Participation -- Potential Benefit #8: Establishment of a Cognitive Baseline -- The Key Question: Can Earlier Intervention in Dementia Make a Difference? -- SECTION 2: BEDSIDE TESTS FOR DEMENTIA SCREENING -- The Mini-Mental State [44] -- Montreal Cognitive Assement (MoCA) [47] -- The Clock Draw Test -- The Mini-Cog [58] -- Buschke's Memory Impairment Screen [61] -- Semantic and Lexical Fluency Tasks as Screening Tools.

The Hopkins Verbal Learning Test (HVLT) [71] -- The Q&amp -- E (Quick and Easy) -- CONCLUSION -- NOTES -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Endothelial Dysfunction and Chronic Low-Grade Inflammation as Potential Therapeutic Targets in Dementia Disorders -- INTRODUCTION -- Endothelial Dysfunction and Chronic Low-Grade Inflammation as a Possible Link between Cardiometabolic Disorders and Dementia -- Endothelial Dysfunction and Dementia -- Treatment Options Targeting Endothelial Dysfunction and Chronic Low-Grade Inflammation in Dementia Disorders -- Endothelin Receptor Antagonists -- Anti-Inflammatory Drugs -- Nonsteroidal Anti-Inflammatory Drugs -- Cytokine Suppressive Anti-Inflammatory Drugs -- CONCLUSION -- ACKNOWLEDGEMENTS -- CONFLICT OF INTEREST -- REFERENCES -- Recent Clinical Developments in Alzheimer's Disease -- INTRODUCTION -- Therapeutic Strategies and Clinical Trials -- Cholinergic Hypothesis -- Amyloid Cascade Hypothesis -- Inflammation in AD -- Metal Dyshomeostasis in AD -- Future Development: Challenges and Recent Advances -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- ABBREVIATIONS -- REFERENCES -- Recent Perspective About the Amyloid Cascade Hypothesis and Stem Cell-Based Therapy in the Treatment of Alzheimer's Disease -- ALZHEIMER'S DISEASE PATHOPHYSIOLOGY -- GENERAL VIEW ABOUT AD -- GENETIC BASIS OF AD AND AMYLOID CASCADE THEORY -- The Amyloid Cascade Hypothesis -- Argument Against the Amyloid Cascade Hypothesis -- Stem Cell-Based Therapy for AD -- Neural Stem Cell-Based Therapy for AD -- Induced Pluripotent Stem Cell-Based Therapy for AD -- Expert View and Future Perspectives -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Current Concepts in Management of Alzheimer's Disease -- INTRODUCTION -- EPIDEMIOLOGY -- SYMPTOMS AND DISEASE COURSE -- Early Stage -- Moderate Stage -- Advanced Stage.

DISEASE CAUSES AND MECHANISMS -- Genetics -- Cholinergic Hypothesis -- Amyloid Hypothesis -- Tau Hypothesis -- Other Hypotheses -- NEUROPATHOLOGY -- BIOCHEMISTRY -- DISEASE MECHANISMS -- DIAGNOSIS -- Early Diagnosis -- PREVENTION -- MANAGEMENT -- Medications -- Psychosocial Intervention -- Caregiving -- PROGNOSIS -- SOCIOECONOMIC BURDEN -- Caregiving Burden -- TREATMENTS UNDER RESEARCH -- MILD COGNITIVE IMPAIRMENT -- Diagnosis -- Treatment -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- Natural Compounds from Plants Targeting Alzheimer's Disease -- INTRODUCTION -- PATHOPHYSIOLOGICAL MECHANISMS -- Beta-Amyloid and Tau Proteins -- Neurotransmitters -- Hypothalamic-Pituitary-Adrenal Axis -- Oxidative Stress -- Inflammation -- Metal Hypothesis -- Endothelial Dysfunction -- Insulin Dysfunctions -- NATURAL PRODUCTS -- Vitis vinifera -- Punica granatum L -- Curcuma longa -- Camellia sinensis -- Olea europaea -- Salvia miltiorrhiza -- Ginkgo biloba -- Melissa Officinalis -- METHODS FOR ANALYSIS OF BIOACTIVE COMPOUNDS -- Sample Preparation -- Overview of Extraction Methods -- Phenolic Acids and Tannins Extraction -- Stilbenes Extraction -- 3.2.3. Curcuminoids Extraction -- Catechins Extraction -- Triterpenes Extraction -- Lactones Extraction -- Quantification of Bioactive Compounds -- Phenolic Acids and Tannins Quantification -- Stilbenes Quantification -- Curcuminoids Quantification -- Catechines Quantification -- Triterpenes Quantification -- Lactones Quantification -- CONCLUSION -- CONFLICT OF INTEREST -- ACKNOWLEDGEMENTS -- REFERENCES -- SUBJECT INDEX.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.